Polaris Genomics

Cover Block

PUBLIC

Attribute	Value
Name	Polaris Genomics
Tagline	Mental health biomarker platform using AI-genomics from blood samples
Headquarters	Gaithersburg, Maryland
Founded	2017
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founders	Charles Cathlin, Tshaka Cunningham
Funding Label	Seed
Total Disclosed	~$3.4M

Links

PUBLIC

• Website: https://polarisgenomics.com
• LinkedIn: https://www.linkedin.com/company/polarisgenomics

Executive Summary

PUBLIC

Polaris Genomics is building a biomarker discovery platform for mental health, a bet that the field of psychiatry will shift from subjective assessment toward objective, biology-based diagnostics and therapeutic development. The company's ADAPT platform uses a targeted gene panel and machine learning to identify molecular signatures for conditions like PTSD, depression, and anxiety from blood samples, a method it claims is a first-to-market approach [Polaris Genomics]. This thesis is backed by a founding narrative rooted in personal experience, with co-founder and CEO Charles Cathlin's motivation stemming from his time stationed at Ground Zero after 9/11 [Illumina]. The scientific leadership, including Chief Scientific Officer Tshaka Cunningham, a molecular biology PhD from Rockefeller University, provides the technical foundation [Polaris Genomics].

To date, the company has secured approximately $3.4 million in seed-stage capital from a notable syndicate that includes Viking Global Investors, Wing Venture Capital, and Sanford Health, alongside non-dilutive support from programs like the Illumina Accelerator and JLABS [Crunchbase, TEDCO]. The business model is B2B, targeting biotech and pharmaceutical companies as initial customers for its patented PTSD risk assay, positioning itself as a research tool rather than a direct-to-consumer diagnostic. Over the next 12-18 months, the critical watchpoints will be the validation of its biomarker signatures through published research, the announcement of its first commercial partnerships with named pharmaceutical entities, and its ability to translate academic and accelerator credibility into a repeatable commercial motion.

Data Accuracy: YELLOW -- Key company claims are self-reported; funding details are corroborated by multiple databases but lack independent press verification.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Funding	Seed (total disclosed ~$3,400,000)

Company Overview

PUBLIC

Polaris Genomics was founded in 2017 as a veteran-owned biotech startup, with its mission rooted in a founder's direct experience at Ground Zero after the 9/11 attacks [Illumina]. The company is headquartered in Gaithersburg, Maryland, and positions itself as a precision mental health company focused on integrating genomics and AI to discover biomarkers for conditions like PTSD and depression [Polaris Genomics]. Its founding narrative, as detailed on its website, is driven by the perceived gap in objective, biology-based tools for psychiatry [Polaris Genomics].

Key operational milestones include participation in the Illumina Accelerator program, which provided early access to sequencing technology and support [Illumina]. The company also secured a place in the Johnson & Johnson Innovation JLABS network in 2022, an award that included non-dilutive funding and mentorship [Polaris Genomics]. In 2023, Polaris Genomics received a $500,000 investment from TEDCO's SSBCI program to support its biomarker discovery platform [TEDCO, August 2023].

Data Accuracy: YELLOW -- Company website and press releases provide the narrative, with some milestones corroborated by third-party sources like TEDCO and Illumina. Founder details and specific founding dates are less consistently reported outside the company's own materials.

Product and Technology

MIXED

Polaris Genomics positions its core offering as the ADAPT Neuropsychiatric Biomarker Discovery Platform. The company describes this as a targeted gene panel analyzed via next-generation sequencing and machine learning to identify biomarker signatures from blood samples for conditions including PTSD, depression, anxiety, ADHD, traumatic brain injury, and substance use disorder [Polaris Genomics]. The stated goal is to provide biological clarity and objectivity to the assessment, diagnosis, and treatment of mental health, a field historically lacking molecular biomarkers [Polaris Genomics].

The platform's initial commercial wedge is a patented PTSD risk assay, which the company calls first-to-market [Polaris Genomics]. This assay is sold to biotech and pharmaceutical researchers, R&D services, and developers of mental health diagnostics and therapeutics [Polaris Genomics]. The company claims its proprietary panel of neuropsychiatric biomarkers provides insights that whole transcriptome methods cannot, though specific performance data or validation studies are not publicly detailed [Polaris Genomics].

Technology partnerships form a visible part of the product narrative. Polaris Genomics has collaborated with the Illumina Accelerator, scientists from Mount Sinai, and researchers from the Max Planck Institute of Psychiatry [Polaris Genomics, Illumina]. These relationships suggest a foundation in genomic sequencing and academic research, though the specific outputs or integrated tools from these partnerships are not disclosed.

Data Accuracy: YELLOW -- Product claims sourced solely from company materials; partnerships with named institutions provide partial corroboration.

Market Research and Opportunity

PUBLIC

The push for objective biology in mental health diagnostics, a field historically reliant on subjective self-reporting, is creating a new commercial frontier for biomarker discovery.

Quantifying the total addressable market (TAM) for mental health biomarkers is complex, as it spans clinical diagnostics, pharmaceutical R&D tools, and digital health applications. For context, the broader global mental health market was valued at $383.3 billion in 2020 and is projected to reach $537.9 billion by 2030, according to a report from Allied Market Research [Allied Market Research, 2021]. The specific segment for precision psychiatry and biomarker-based tools is nascent but growing, often benchmarked against analogous markets in oncology. For example, the global market for companion diagnostics, which includes biomarker tests used to guide cancer therapy, was estimated at $5.6 billion in 2022 and is projected to reach $13.6 billion by 2030 [Grand View Research, 2023]. This provides a relevant, if imperfect, analog for the potential scale of a platform targeting biomarker discovery for therapeutic development in mental health.

Demand is driven by several converging tailwinds. There is increasing recognition of the economic and societal burden of mental health conditions, which the World Health Organization estimates cost the global economy $1 trillion per year in lost productivity [World Health Organization, 2022]. Concurrently, regulatory bodies like the U.S. Food and Drug Administration (FDA) have shown a growing openness to novel biomarker endpoints in clinical trials, particularly in areas of high unmet need such as post-traumatic stress disorder (PTSD) and treatment-resistant depression [FDA, 2022]. The expansion of next-generation sequencing (NGS) infrastructure and declining costs of genomic analysis have also made large-scale biomarker discovery more commercially feasible than in prior decades.

Key adjacent markets that could serve as substitutes or expansion vectors include the broader digital therapeutics and telehealth sectors, which offer behavioral interventions without a biological component, and the established market for genetic risk assessments from companies like 23andMe. The regulatory pathway for a diagnostic assay is distinct and more stringent than for a wellness report, representing both a barrier and a potential source of defensibility. Macro forces, including increased focus on veteran health and a post-pandemic emphasis on mental wellness, are creating specific funding and partnership opportunities within defense and public health channels.

Global Mental Health Market 2020 | 383.3 | $B
Projected Mental Health Market 2030 | 537.9 | $B
Companion Diagnostics Market 2022 | 5.6 | $B
Projected Companion Dx Market 2030 | 13.6 | $B

The sizing analogs suggest the core biomarker discovery opportunity exists within a multi-billion dollar envelope, but its capture depends entirely on clinical validation and adoption within the pharmaceutical R&D workflow, a process measured in years, not quarters.

Data Accuracy: YELLOW -- Market sizing relies on third-party analyst reports for analogous sectors; specific TAM for neuropsychiatric biomarkers is not publicly defined by the company or a cited source.

Competitive Landscape

MIXED Polaris Genomics operates in a nascent but increasingly crowded segment, attempting to build a defensible position at the intersection of genomics, AI, and mental health diagnostics.

The competitive map is fragmented across distinct business models and scientific approaches. The company's primary competition is not direct, but rather from established players in adjacent markets and a new wave of research-focused startups.

• Incumbent diagnostic giants. Companies like Genomic Health (now part of Exact Sciences) and Guardant Health have validated the liquid biopsy model in oncology, demonstrating the commercial viability of blood-based genomic tests for disease management. Their scale, regulatory experience, and entrenched sales channels in oncology present a formidable barrier to entry for any new diagnostic player, though they are not currently focused on neuropsychiatry.
• Direct-to-consumer genomics. 23andMe has built a massive consumer genetics database and has research programs in areas like depression and PTSD. Their model is predicated on consumer consent and broad population data, which differs from Polaris's targeted, clinical-grade biomarker discovery for pharmaceutical and research clients. The competitive threat lies in 23andMe's potential to pivot its vast dataset toward clinical research partnerships.
• Emerging research tools and AI platforms. A newer cohort of startups is applying multi-omics and machine learning to brain health. While no specific private competitors were surfaced in the research for this report, the field includes companies exploring digital biomarkers, neuroimaging analytics, and other modalities beyond blood-based genomics. Polaris's stated edge is its specific focus on a curated panel for neuropsychiatric conditions, as opposed to a broader discovery approach.

Where Polaris has a potential edge today is in its early academic and institutional partnerships. Collaborations with the Illumina Accelerator, Mount Sinai, and the Max Planck Institute [Polaris Genomics] provide scientific credibility and access to specialized research cohorts, particularly in trauma-related disorders. This network is a perishable advantage, however, as larger players with deeper pockets can form similar or more extensive alliances.

The company is most exposed in two areas. First, it lacks the commercial infrastructure and regulatory track record of its publicly traded counterparts in the diagnostics space. Bringing a test to market as a regulated diagnostic requires significant capital and time, areas where well-funded incumbents hold a decisive advantage. Second, its focus on a proprietary panel could be circumvented by competitors using whole transcriptome or other discovery methods that later identify the same biomarkers, potentially eroding the uniqueness of its core asset.

The most plausible 18-month competitive scenario hinges on partnership momentum. If Polaris can convert its academic collaborations into a flagship partnership with a major pharmaceutical company for biomarker discovery, it would validate its platform and create a defensible revenue moat. In this case, a "winner" could be a nimble startup like Polaris that secures an exclusive pharma deal. Conversely, if progress stalls and a larger entity like 23andMe or a diagnostic incumbent announces a competing mental health biomarker program with similar academic backing, Polaris would be the "loser," as its early-mover status and niche focus may not be enough to compete with established commercial engines.

Data Accuracy: YELLOW -- Competitive positioning is inferred from company claims and known market players; specific competitive intelligence is limited.

Opportunity

PUBLIC

If Polaris Genomics can translate its foundational research into a clinically validated diagnostic, it would capture a first-mover position in a market that has, for decades, lacked objective biological measures for mental health.

The headline opportunity is to become the foundational biomarker discovery platform for precision psychiatry, analogous to what Guardant Health did for liquid biopsy in oncology. The company’s core thesis, that mental health diagnostics can be built on molecular biomarkers from blood, addresses a critical gap in psychiatry [Polaris Genomics]. Its initial focus on a patented PTSD risk assay provides a specific, defensible wedge into the research market, selling to biotech and pharmaceutical companies for drug development and companion diagnostics [Polaris Genomics]. The plausibility of this outcome is supported by the company’s participation in credible accelerator programs like Illumina Accelerator and JLABS, which provide technical validation and access to industry networks [Polaris Genomics, Illumina]. The presence of investors like Viking Global Investors and Wing Venture Capital, firms with long-term biotech track records, signals institutional belief in the underlying science, even in the absence of commercial metrics [Crunchbase].

Growth from this research-focused starting point could follow several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Diagnostic Regulatory Approval	The PTSD assay transitions from a research tool to an FDA-cleared diagnostic test for clinical use.	Successful completion of a pivotal clinical validation study, likely funded by a strategic partner or a larger financing round.	The company’s foundational partnerships with academic institutions like Mount Sinai and the Max Planck Institute provide the scientific credibility and access to patient cohorts necessary for such studies [Polaris Genomics].
Pharma Platform Partnership	A major pharmaceutical company licenses the ADAPT platform to identify biomarkers for drug response across a portfolio of CNS candidates.	Announcement of a multi-year R&D collaboration with a named pharma partner, similar to early deals in the genomic diagnostics space.	The company’s stated business model targets biotech and pharma researchers, and its selection for JLABS provides direct mentorship and networking within Johnson & Johnson’s ecosystem [Polaris Genomics].
Government/VA Adoption	The U.S. Department of Veterans Affairs adopts the PTSD test as a standard screening tool, creating a large, captive initial market.	A contract award following a demonstration project, leveraging the veteran-owned status and mission-driven narrative of the founders.	CEO Charles Cathlin’s veteran background and direct advocacy, including participation in podcasts with former VA Secretary Dr. David Shulkin, align the company’s mission with this specific buyer [EisnerAmper].

Compounding success in any of these scenarios would build a data moat that accelerates the platform’s core value. Each new clinical sample processed through the ADAPT platform would refine the AI models, improving the accuracy and expanding the panel of biomarkers for additional conditions like depression or anxiety. This creates a classic biotech flywheel: better data leads to more validated biomarkers, which attracts more pharmaceutical partners and clinical studies, which in turn generates more proprietary data. Early signs of this flywheel are suggested by the company’s ongoing scientific team expansion, as noted in a blog post highlighting a new team member [Polaris Genomics]. While still early, the deliberate focus on building a proprietary panel, as opposed to using whole transcriptome methods, is explicitly framed as a competitive advantage meant to create these compounding insights [Polaris Genomics].

The size of the win, should the diagnostic approval scenario play out, can be contextualized by looking at comparable companies in precision medicine. Guardant Health, a leader in liquid biopsy for cancer, reached a market capitalization of several billion dollars following the commercialization of its FDA-approved tests. While Polaris operates in the nascent neuropsychiatric biomarker space, the total addressable market for mental health diagnostics is substantial. A successful platform that becomes the standard for objective assessment in even a subset of conditions like PTSD or treatment-resistant depression could support a valuation in the hundreds of millions to low billions, based on precedent in adjacent diagnostic markets (scenario, not a forecast). This outcome remains highly contingent on clinical and regulatory success, but the foundational pieces,patented science, strategic partnerships, and mission-aligned capital,are in place to make the pursuit credible.

Data Accuracy: YELLOW -- Core opportunity thesis is drawn from company statements and partner affiliations; growth scenarios are plausible extrapolations based on the business model but lack specific, dated catalyst announcements from independent press.

Sources

PUBLIC

1. [Allied Market Research, 2021] Global Mental Health Market Report | https://www.alliedmarketresearch.com/mental-health-market-A12754

2. [Crunchbase] Polaris Genomics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/polaris-genomics-830d

3. [EisnerAmper] How Health Care Advances for Veterans | https://www.eisneramper.com/insights/health-care/health-care-advances-veterans-podcast-0322/

4. [FDA, 2022] FDA Guidance on Biomarker Endpoints | https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. [Grand View Research, 2023] Companion Diagnostics Market Size Report | https://www.grandviewresearch.com/industry-analysis/companion-diagnostics-market

6. [Illumina] Polaris Genomics seeks to reveal invisible wounds | https://www.illumina.com/company/news-center/feature-articles/polaris-genomics-seeks-to-reveal-invisible-wounds-.html

7. [Polaris Genomics] About Us - Polaris Genomics | https://polarisgenomics.com/about-us/

8. [Polaris Genomics] From Ground Zero to Genomics: Charles Cathlin's Story | https://polarisgenomics.com/from-ground-zero-to-genomics-charles-cathlins-story/

9. [Polaris Genomics] Genomic-Led Health Meets People Where They Are, an Illumina Interview | https://polarisgenomics.com/genomic-led-health-meets-people-where-they-are-an-illumina-interview/

10. [Polaris Genomics] Home - Polaris Genomics | https://polarisgenomics.com/

11. [Polaris Genomics] Invest - Polaris Genomics | https://polarisgenomics.com/invest/

12. [Polaris Genomics] Our Milestones & Mission Move Us Forward | https://polarisgenomics.com/our-milestones-mission-move-us-forward/

13. [Polaris Genomics] Partnerships - Polaris Genomics | https://polarisgenomics.com/partnerships/

14. [Polaris Genomics] Polaris Genomics Advances Mental Health Biomarker Discovery | https://polarisgenomics.com/polaris-genomics-advances-mental-health-biomarker-discovery/

15. [Polaris Genomics] Redefining how mental health is understood and treated | https://polarisgenomics.com/redefining-how-mental-health-is-understood-and-treated/

16. [Polaris Genomics] Strengthening Our Scientific Team: Meet Nikolaos Daskalakis | https://polarisgenomics.com/strengthening-our-scientific-team/

17. [TEDCO, August 2023] TEDCO Announces SSBCI Investment in Polaris Genomics | https://www.tedcomd.com/news-events/press-releases/2023/tedco-announces-ssbci-investment-polaris-genomics

18. [World Health Organization, 2022] Mental health at work | https://www.who.int/news-room/fact-sheets/detail/mental-health-at-work